# Symrise FactBook

 $\langle\!\!\langle$ 



1	Who is Symrise? – From Past to Present	3
2	Divisions and Business Units	10
3	Investment Case	17
4	Corporate Governance	28
5	Employees	42
6	Strategy	47
7	Financials	70



1

# **Corporate governance** *Dual management system*

#### **Competencies**


**Executive Board** responsible for managing the company's business operations in the interest of the company with a view to create sustainable value for all stakeholders.

**Supervisory Board** advises and oversees the Executive Board. It is involved in strategy and planning as well as all other decisions of fundamental significance to the company.

#### **Dual Management System**

**Dual board** in accordance with German Corporate Law (Co-determination) and Corporate Governance Codex 2020. Both bodies cooperate closely and in a spirit of trust in managing and overseeing the company.

### **Two-tier system**



\*In accordance with the German Co-determination Act, a supervisory board with six employee representatives must include four employee representatives of the company and two union representatives.

### **Executive Board** *Representatives*

Updated, May 2023



**Dr. Heinz-Jürgen Bertram** Chief Executive Officer (appt. until October 2025)

- Born 18/09/1958 in Landwehr
- Degree and PhD in Chemistry in 1987
- Joined Haarmann & Reimer in 1985
- Various management positions within the company
- Board member since 2006 and CEO since 2009



**Olaf Klinger** Chief Financial Officer (appt. until January 2028)

- Born 09/05/1965 in Heide
- Awarded degree in business administration in 1992
- Various finance positions for other companies (e.g. Merck, AMEOS group)
- Joined Symrise in 2016 as a Board member and CFO



**Dr. Stephanie Cossmann** Board member for HR & Legal and Labor Director (appt. until January 2026)

- Born 02/10/1973 in Hanover
- Degree and PhD in Law in 2002
- Years of experience in Human Resources & Legal at LANXESS
- Joined Symrise in 2023 as a Board member



**Dr. Jörn Andreas** Board member for Scent & Care (appt. until January 2026)

- Born 05/12/1980 in Hameln
- Degree and PhD in Economic Sciences in 2010
- Years of experience at Bayer and BCG and various management positions within the company
- Joined Symrise in 2011
- Board member since 2023



**Dr. Jean-Yves Parisot** Board member for Taste, Nutrition & Health (appt. until September 2024)

- Born in 07/02/1964 in Lunéville, France
- Degree in veterinary medicine & MBA HEC Paris
- Various management positions (e.g. at Air Liquide, Danisco)
- Joined Symrise in 2014 via Diana
- Board member since 2016



# **Supervisory Board** *Representatives*

Updated, May 2023

<b>Michael König</b> * 03/09/1963 in Iserlohn CEO Nobian Industrial Chemicals B.V. Since 2020 (Chairman since 2020)	Harald Feist * 05/11/1962 in Stadtoldendorf Chairman of the works council and Chairman of the general works council at Symrise AG Since 2013 (Vice Chairman since 2018)	<b>Ursula Buck</b> * 24/10/1961 in Ulm Managing Director of Top Managementberatung BuckConsult Since 2016	<b>Jeannette Chiarlitti</b> * 15/03/1982 in Schoenebeck Deputy Regional Head of IG BCE for the North region Since 2016
André Kirchhoff * 20/08/1965 in Stadtoldendorf Independent member of the works council at Symrise AG Since 2016	<b>Bernd Hirsch</b> * 24/07/1970 in Ellwangen CFO COFRA AG Since 2018	<b>Dr. Jakob Ley</b> * 01/03/1967 in Bonn Director Research Biobased Ingredients Research & Technology Taste, Nutrition & Health at Symrise AG Since 2021	<b>Jan Zijderveld</b> * 09/05/1964 in Ede Professional Supervisory Board Member Since 2023
<b>Prof. Dr. Andrea</b> <b>Pfeifer</b> * 26/09/1957 in Munich CEO AC Immune S.A. Since 2011	Andrea Püttcher * 04/10/1977 in Holzminden Vice Chairperson of the works council and Vice Chairperson of the general works council at Symrise AG Since 2018	<b>Peter Vanacker</b> * 11/03/1966 in Wervik CEO LyondellBasell. Since 2020	Malte Lückert * 03/02/1988 in Soltau Secretary of the Executive Board, Division 2 for Economic, Sectoral & Collective Bargaining Policy and HR, IG BCE since 2023

The maximum term of office for a Supervisory Board member is

### four years

and must end at the conclusion of the AGM following the member's

70th birthday.

The maximum limit for membership in the Supervisory Board is four terms of office.

Read the Rules of Procedure for the Supervisory Board <u>here</u>.

#### 4. Corporate Governance

# **Supervisory Board – Qualification matrix (as of Dec 31, 2022)** *Shareholder representatives*



Matrix in accordance with section C.1 of the German Corporate Governance Code 2022. <sup>1</sup> In accordance with section C.4 & C.5 of the German Corporate Governance Code 2022.

 ${}^{2}$ F = Female, M = Male.



# **Supervisory Board – Qualification matrix (as of Dec 31, 2022)** *Employee representatives*



	Ro	ole								C	ompet	ences						Dive	ersity crit	eria
					Indus -try				F	unction	al					ESG				
	Independency	Initial election	End of term (AGM)	Overboarding <sup>1</sup>	Experience in Taste, Nutrition & Health, Scent & Care	Human Resources	General management	Production & raw materials	Financial expert	Quality / Regulatory / Risk management	International experience	Innovation / R&D management	Executive position	IT & IT security expertise	Environmental	Social /Safety at work / Health protection	Governance	Year of birth	Nationality	Gender <sup>2</sup>
Jeannette Chiarlitti	No	2016	2026	No		$\checkmark$		$\checkmark$								$\checkmark$	$\checkmark$	1982	German	F
Harald Feist (Vice Chairman)	No	2013	2026	No	✓	$\checkmark$		$\checkmark$		$\checkmark$					$\checkmark$	$\checkmark$	$\checkmark$	1962	German	М
André Kirchhoff	Yes	2016	2026	No	<b>v</b>	$\checkmark$		$\checkmark$								<b>v</b>	$\checkmark$	1965	German	М
Dr. Jakob Ley	No	2021	2026	No	✓			$\checkmark$		$\checkmark$		<b>v</b>			$\checkmark$	$\checkmark$	$\checkmark$	1967	German	М
Andrea Püttcher	No	2018	2026	No	<b>v</b>	$\checkmark$		$\checkmark$								<b>v</b>	$\checkmark$	1977	German	F
Peter Winkelmann	Yes	2006 <sup>3</sup>	2026	No	<b>v</b>	$\checkmark$		$\checkmark$								$\checkmark$	$\checkmark$	1958	German	М

Matrix in accordance with section C.1 of the German Corporate Governance Code 2022. <sup>1</sup> In accordance with section C.4 & C.5 of the German Corporate Governance Code 2022. <sup>2</sup> F = Female, M = Male. <sup>3</sup> 2006-2011 and since May 14, 2014.

### **Supervisory Board**

Six experienced shareholder representatives





**Michael König** (\*1963) Graduate Engineer in Chemical Process Engineering, Univ. Dortmund

CEO Nobian Industrial Chemicals B.V.

**Expert in** Chemistry, ESG and broad international expertise in Asia, especially China



**Bernd Hirsch** (\*1970) Degree in Business Economics, University of Würzburg

CFO COFRA AG

**Expert in** Finance (profound knowledge of internal company processes) and IT



**Ursula Buck** (\*1961) Degree in Business Economics, University of Augsburg

Managing Director of Top Managementberatung BuckConsult

**Expert in** Fragrances, fast-moving consumer goods industry, brands and brand communication



**Prof. Dr. Andrea Pfeifer** (\*1957) PhD in Toxicology, Univ. Würzburg; habilitation University of Lausanne

CEO AC Immune S.A.

**Expert in** Life Science and Bio-Technology, especially Nutrition and consumer health



Jan Zijderveld (\*1964) Degree in Business Management, University of Waikato

Professional Supervisory Board Member

**Expert** in Food & Beverages and Scent & Care, fast-moving consumer goods industry, brand and marketing



**Peter Vanacker** (\*1966) MSc. Chemical Engineering, University of Gent

CEO LyondellBasell.

**Expert in** green chemistry, ESG, lean processing, cyber security, and broad international expertise esp. Americas

Read the supervisory board members' full CVs here.

# Supervisory Board (as of Dec 31, 2022)

Committees and its members



### Personnel Committee

Responsible for matters pertaining to the Executive Board including the appointment of new members, succession planning and the development of the remuneration system.

### Members Michael König · Chairman

Harald Feist

Horst-Otto Gerberding

Dr. Jakob Ley

Prof. Dr. Andrea Pfeifer

Peter Winkelmann

### Auditing Committee

Focuses on matters relating to the annual financial statements including monitoring of the accounting process, effectiveness of the internal controlling and risk management system and independence of the auditor.

### Members

Bernd Hirsch · Chairman Ursula Buck Jeannette Chiarlitti Harald Feist Michael König

Andrea Püttcher

### Arbitration Committee

Makes a proposal in case no two-third majority is reached for the appointment or the cancellation of an appointment of Executive Board members.

### Nominations Committee

Recommends suitable candidates to represent shareholders when new Supervisory Board elections are coming up.

### Members

Michael König · Chairman Ursula Buck Harald Feist André Kirchhoff

### Members

**Michael König** · Chairman Horst-Otto Gerberding

Prof. Dr. Andrea Pfeifer

### **Supervisory Board**

### attendance rate in meetings during the 2022 fiscal year\*

Member name	Supervisory Board Meeting (Total: 6)
Michael König (Chairman)	100 %
Ursula Buck	100 %
Jeannette Chiarlitti	100 %
Harald Feist	100 %
Horst-Otto Gerberding	100 %
Bernd Hirsch	100 %
André Kirchhoff	100 %
Dr. Jakob Ley	100 %
Prof. Dr. Andrea Pfeifer	100 %
Andrea Püttcher	100 %
Peter Vanacker	100 %
Peter Winkelmann	100 %

Member name	Personnel Committee (Total: 3)	
Michael König (Chairman)	100 %	
Harald Feist	100 %	
Horst-Otto Gerberding	100 %	
Dr. Jakob Ley	100 %	
Prof. Dr. Andrea Pfeifer	100 %	
Peter Winkelmann	100 %	

Member name	Audit Committee (Total: 5)
Bernd Hirsch (Chairman)	100 %
Ursula Buck	100 %
Jeannette Chiarlitti	100 %
Harald Feist	100 %
Michael König	100 %
Andrea Püttcher	100 %

	Supervisory Board Meeting (Total: 6)	Personnel Committee (Total: 3)	Audit Committee (Total: 5)
In Person	33 %	100 %	20 %
Hybrid	67 %	0 %	80 %

### **Executive Board**



# New remuneration system 2022 compared to remuneration system 2021

Aspect	Adjustment	Reason for adjustment
Remuneration structure	<ul> <li>New target remuneration structure:</li> <li>Fixed remuneration: 30% (previously 35%)</li> <li>Short-term incentive: 30% (previously 30%)</li> <li>Long-term incentive: 40% (previously 35%)</li> </ul>	<ul> <li>Even stronger focus on the company's long-term development</li> <li>Strengthening the pay-for-performance link of the remuneration system</li> </ul>
Short-term incentive	<ul> <li>Specification of the financial performance criteria and their weighting:</li> <li>organic net sales growth (30%)</li> <li>EBITDA margin (30%)</li> <li>business free cash flow as % of sales (20%)</li> </ul>	<ul> <li>Reduced complexity due to the reduction of financial performance criteria</li> <li>Significant increase in transparency as concrete financial performance criteria and weightings are determined in the remuneration system and disclosed</li> </ul>
Long-term incentive	<ul> <li>Use of performance share plan (previously performance cash plan)</li> <li>Performance period extended from three to four years</li> <li>Earnings per share and ESG goals included as performance criteria in addition to relative TSR (previously only relative TSR)</li> <li>No accelerated vesting in case of change of control</li> </ul>	<ul> <li>Stronger link to the share price development of Symrise</li> <li>Increased alignment with wider shareholder and stakeholder interests</li> <li>Stronger long-term orientation</li> <li>Increased focus on profitability and sustainability</li> <li>Alignment with German Corporate Governance Code recommendations</li> </ul>
Other contractual aspects	<ul> <li>Maximum remuneration at €5.2 million for CEO and €3.4 million for ordinary Executive Board members</li> <li>Decreased severance pay cap from three to two years (also in case of change of control), still limited to remaining term</li> <li>Offsetting of termination benefits against waiting allowance</li> </ul>	<ul> <li>Level of maximum remuneration in line with market practice</li> <li>Alignment with German Corporate Governance Code recommendations and consideration of best practice</li> </ul>

# **Remuneration System** *Performance-related components*



Remuneratio	on component	Assessment basis/ parameters	
Performance-	Short-term incentive (STI) (30%)*	<ul> <li>Type: Target bonus</li> <li>Term: one year</li> <li>Performance criteria: <ul> <li>Financial criteria: net sales growth (30 %), EBITDA margin (30 %) and business free cash flow (20 %)</li> <li>Non-financial criteria (20 %) ESG goals and strategic goals</li> </ul> </li> <li>Cap: 150 % of the target amount</li> <li>Payment form: cash</li> <li>No special bonuses</li> </ul>	150 % 150 % 0 % Thres- Target Max. value Value Performance
related (70%)*	Long-term incentive (LTI) (40%)*	<ul> <li>Type: performance share plan (annual tranches)</li> <li>Term: four years</li> <li>Performance criteria: <ul> <li>Financial criteria: relative TSR (40 %) and EPS (40 %)</li> <li>Non-financial criteria (20 %) ESG goals</li> </ul> </li> <li>Cap: 200 % of the target amount</li> <li>Payment form: cash or shares</li> </ul>	200 % % 000 goal achievement 200 % % 000 goal achievement 0 % 0 % 0 % 75 % Symrise percentile rank

# **Remuneration System** *Non-performance-related components*



Remuneration component		Assessment basis/ parameters
	Fixed remuneration	Contractually agreed fixed amount, which will as a rule be paid out in twelve equal monthly amounts
Non- performance- related	Supplementary payments	<ul> <li>Supplementary payments in the form of fringe benefits, in particular:         <ul> <li>Company car, including for private use</li> <li>Contributions to a group accident insurance policy (death/invalidity)</li> <li>Employer contribution to social security</li> </ul> </li> <li>For persons joining Symrise, in some cases payments compensating for forfeiture of variable remuneration from a previous employer or other financial disadvantages</li> </ul>
(30%)*	Retirement provision	<ul> <li>No company-funded pension plan for Executive Board members</li> <li>Ability to accumulate deferred compensation retirement benefits through salary conversion</li> <li>There may be some individual contractual pension commitments due to previous employment relationships with the company</li> </ul>

### **Remuneration System**

# Peer group and ESG/ strategic goals example



### Peer Group

	Relative TSR –	peer group	
Beiersdorf	Givaudan	LANXESS	CHR Hansen
Henkel	Novozymes	Croda	IFF
Südzucker	DSM	Kerry Group	Wacker Chemie
Evonik	KWS		
Keeping state-of-th	Other contract Malus & Clawback e-art performance and compliance malus & clawba variable remuneration		
Determination c	Maximum remuneration f maximum remuneration (CEO: €5.2 million and Or Members: €3.5 million)		suring ulatory
	<b>Severance payments</b> ents are limited to a maximum of two years' remun g term of the contract (also in case of change of co	eration or the CON	formity
Seve	<b>Offset of severance payments</b> rance payments are offset against compensation fo postemployment noncompete clause	r	

### Authorized and Conditional Capital

Authorization to issue up to 40.56m shares



